<DOC>
	<DOCNO>NCT02132988</DOCNO>
	<brief_summary>The purpose study evaluate effect OPT-822/OPT-821 improve Progression-Free Survival ( PFS ) subject non-progressive epithelial ovarian , fallopian tube , primary peritoneal cancer cytoreductive surgery platinum-based chemotherapy initial treatment primary disease salvage treatment first relapse .</brief_summary>
	<brief_title>Trial Active Immunotherapy With Globo H-KLH ( OPT-822/821 ) Women Who Have Non-Progressive Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Female subject ≥ 21 year age histologically confirm ≥ stage II epithelial ovarian , fallopian tube , primary peritoneal cancer diagnosis Who progress initial treatment cytoreductive surgery least 4 cycle platinumbased chemotherapy . OR Female subject ≥ 21 year age first relapse epithelial ovarian , fallopian tube , primary peritoneal cancer ( regardless stage diagnosis ) Who progress receive least 4 additional cycle platinumbased chemotherapy without undergone secondary cytoreductive surgery . Subjects evidence disease progression accord GCIG CA125 criterion RECIST 1.1 criterion . Subjects currently receive concomitant anticancer therapy . Subjects evidence extraabdominal metastasis .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>